BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA ...

A BridgeBio Pharma drug developed for an increasingly prevalent cardiovascular condition has won FDA approval, marking a comeback for a company and a molecule with a turbulent history. But BridgeBio’s ...

An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. BridgeBio’s recently ...

Primary results from CALIBRATE, the Phase 3 registrational clinical trial of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) on May 12, 2026 at ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 8 Most Promising Biotech Stocks to Buy Now. On May 8, Evercore ISI raised ...

BridgeBio remains a compelling Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics following Pfizer’s patent settlements. Attruby’s peak annual sales are conservatively ...

CFO Thomas Trimarchi said, "we expect the trend in loss from operations to flatten over the next 2 quarters" as the company ramps launch readiness, and to continue "narrowing towards the end of this ...

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1. PALO ALTO, ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. The Food and Drug ...

Shares of BridgeBio PharmaBBIO are up more than 160% this year as the small biotech company takes on drug behemoths PfizerPFE and Alnylam PharmaceuticalsALNY. Though the company is just 10 years old, ...